Nephrotic syndrome with sunitinib-associated focal segmental glomerulosclerosis in a patient with renal carcinoma: partial reversibility after dose adjustment: Case Report. REV SEN [Internet]. 2025 Aug. 6 [cited 2026 Apr. 25];13(2):149-56. Available from: https://rev-sen.ec/index.php/revista/article/view/118